Breaking News
Investing Pro 0
🙌 It's Here: the Only Stock Screener You'll Ever Need Get Started

EuroAPI gains on market debut after spin-off from Sanofi

Published May 06, 2022 03:13AM ET Updated May 06, 2022 07:01AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: The skyline of La Defense business district is seen during a warm and sunny day as a heatwave combined with pollution led to circulation restrictions in Paris, France, June 25, 2020. REUTERS/Charles Platiau/File Photo 2/2
 
FCHI
+1.87%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
SNY
+1.09%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Ludwig Burger

(Reuters) - Shares in EuroAPI, the drug ingredients business spun off from Sanofi (NASDAQ:SNY), rose on their Paris stock market debut on Friday, defying a wider market decline.

EuroAPI traded at around 12.25 euros at 0915 GMT, valuing the contract manufacturer's equity at 1.15 billion euros ($1.21 billion) and up 2% from its reference price of 12 euros.

The stock premiered in choppy markets, with world stocks falling towards their lowest in over a year as investors anticipated more U.S. interest rate rises and worried about the hit to growth from China's zero-COVID policy.

The STOXX Europe 600 Health Care index was down 1.7%, while France's blue chip index was off 1.5%.

"What a remarkable day it is," said EuroAPI Chief Executive Karl Rotthier after ringing the opening bell in Paris.

"It's my birthday today, that's another good start," added Rotthier, who joined in early 2020 from Dutch pharma ingredients maker Centrient Holding.

Sanofi shareholders will receive one EuroAPI share for 23 shares held in the parent company.

Sanofi shares were down 0.2%, when adjusting for EuroAPI's separation and the payout of a 4.07 billion ordinary dividend.

Sanofi, which will keep a 30% stake, distributed 58% of EuroAPI's equity capital to Sanofi shareholders as a dividend in kind. The French state will acquire 12% in the new company, based on the average market price over the next 30 days.

The group joins rivals including Siegfried and Lonza as stand-alone ingredients and services suppliers to the drugs industry.

As an independent group, EuroAPI has said it will push to win over more of Sanofi's rivals as customers and expand in high-margin drug development services.

Pharma groups that, unlike Sanofi, continue to produce drug ingredients for other drugmakers include Pfizer (NYSE:PFE), Teva and family-owned Boehringer Ingelheim.

EuroAPI's flotation comes as the coronavirus pandemic and Russia's attack on Ukraine have heightened concerns in the European Union over the region's dependency on critical pharma ingredient imports.

($1 = 0.9471 euros)

EuroAPI gains on market debut after spin-off from Sanofi
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email